Eli Lilly and Company (LLY)
NYSE Market Open
Eli Lilly & Co. is a global pharmaceutical company focused on discovering, developing, manufacturing, and commercialising prescription medicines. The company has a long history in diabetes care and has expanded into several high-value therapeutic areas, including obesity, oncology, immunology, neuroscience, and cardiometabolic disease. Lilly sells medicines through healthcare systems, pharmacies, hospitals, and specialist channels in the United States and international markets.
A central part of Lilly’s current profile is its cardiometabolic portfolio. Mounjaro, used for type 2 diabetes, and Zepbound, used for chronic weight management, are based on tirzepatide and have become major growth drivers as demand for GLP-1 and related incretin therapies increases. Lilly also markets established diabetes products such as Trulicity, Jardiance, Humalog, and Humulin, giving it broad exposure across modern and legacy diabetes treatment.
Beyond metabolic disease, Lilly has important positions in cancer and immunology. Verzenio is used in certain breast cancer settings, while Jaypirca targets specific blood cancers. Taltz and Olumiant are part of the company’s immunology franchise, addressing inflammatory and autoimmune conditions. In neuroscience, Lilly is active in areas such as Alzheimer’s disease and migraine, supported by a research pipeline that aims to produce differentiated therapies for complex neurological disorders.
The company’s investment case is closely tied to product innovation, clinical trial execution, regulatory approvals, manufacturing capacity, and pricing dynamics. Lilly competes with other large drugmakers but stands out for the scale of its obesity and diabetes opportunity, its strong research base, and its ability to turn specialised medicines into global commercial franchises.
Last updated
- Market Cap
- $1,051,461,209,229
- P/E
- 41.6
- P/FCF
- 88.93
- P/S
- 14.55
- Enterprise Value
- $1,089,549,209,229
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Address
- LILLY CORPORATE CTR, INDIANAPOLIS, IN, 46285
Sector Update: Healthcare Stocks Fall Late Afternoon
Cathie Wood Is Loading Up on This GLP-1 Stock That Has Soared 1,600% Over the Past 10 Years
IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?
Eli Lilly (LLY) Stock Looks Undervalued On Fair Value Yet Full On Earnings
IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1
Go Big or Go Bigger: Is the Vanguard Mega Cap Growth ETF or S&P 500 Growth ETF the Better Buy?
Weekly Buzz: NVS, MRK Win FDA Nod; LLY Snaps Up ATAI; MANE Shines On Hair Loss Data
The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss
IPO Stock Of The Week: This Eli Lilly Partner Soars 118% In Three Months
Eli Lilly Long-Term GLP-1 Franchise Faces Limited Generic Threat, UBS Says
Looking to diversify away from AI trade? Buy these 3 stocks
Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200
The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea
AtaiBeckley (ATAI) After Eli Lillys Bid Still Looks Fully Valued
Top Biotech Gainers: CDNA Soars On Medicare Policy, ATAI Acquired, ABT Lifts Outlook, APLM On Watch
AtaiBeckley (ATAI) Soars to 4-Year High on $3.8B Merger with Eli Lilly
Eli Lilly Buys AtaiBeckley in $3.8 Billion Deal
AtaiBeckley Soars as Eli Lilly Agrees to $2.8 Billion Buyout
Eli Lilly Likely to See More Momentum in GLP-1 Pipeline, UBS Says
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $1,051,461,209,229
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- $1,089,549,209,229
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 41.6
- P/B
P/B ratio compares a company's share price to its book value per share.
- 33.7
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 14.55
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 30.09
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 15.08
- EPS
- 28.35
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0.53%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 88.93
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 51.34
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- $11,822,900,000
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 81.02%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 21.68%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 1.39
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 1.5
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.1
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.14
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- $3,154,754
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 1,179.11
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 19.8B | 19.29B | 17.6B | 15.56B | 12.73B |
| Cost of revenue | 3.58B | 3.37B | 3.01B | 2.45B | 2.23B |
| Gross profit | 16.22B | 15.92B | 14.59B | 13.11B | 10.5B |
| Operating income | 8.92B | 8.37B | 7.37B | 6.87B | 3.7B |
| EBITDA | 10.29B | 9.57B | 8.86B | 7.5B | 5.77B |
| Net income | 7.4B | 6.64B | 5.58B | 5.66B | 2.76B |
| Income taxes | 1.45B | 1.63B | 1.65B | 1.12B | 697M |
| Other operating expenses | 863M | 612.9M | 1.02B | 153.8M | 1.61B |
| Total operating expenses | 7.31B | 7.55B | 7.23B | 6.24B | 6.81B |
| Basic EPS | 8.27 | 7.4 | 6.22 | 6.3 | 3.07 |
| Diluted EPS | 8.26 | 7.39 | 6.21 | 6.29 | 3.06 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 116.58B | 112.48B | 114.94B | 100.92B | 89.39B |
| Total liabilities | 85.38B | 85.94B | 91.08B | 82.57B | 73.54B |
| Total equity | 31.2B | 26.54B | 23.85B | 18.35B | 15.85B |
| Cash & equivalents | 5.28B | 7.27B | 9.79B | 3.38B | 3.09B |
| Current assets | 54.84B | 55.63B | 62.07B | 49.85B | 41.26B |
| Current liabilities | 36.63B | 35.23B | 40.14B | 39.02B | 30.07B |
| Accounts payable | 5.03B | 5.38B | 4.26B | 4.08B | 3.44B |
| Receivables | 21.18B | 20.16B | 19.46B | 17.21B | 14B |
| Inventories | 14.53B | 13.74B | 12.18B | 11.01B | 9.31B |
| Goodwill | 6.13B | 5.9B | 5.9B | 5.77B | 5.77B |
| Long-term debt | 39.37B | 40.87B | 40.87B | 34.18B | 34.5B |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 5.33B | 3.22B | 8.84B | 3.09B | 1.67B |
| Investing cash flow | -3.92B | -2.8B | -2.98B | -1.83B | -3.35B |
| Financing cash flow | -3.47B | -2.88B | 531M | -1.24B | 1.38B |
| Change in cash | -1.99B | -2.52B | 6.42B | 282.6M | -175M |
| Net income | 7.4B | 6.64B | 5.58B | 5.66B | 2.76B |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| edgar index | 11-K — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Fyrwald J Erik | View Filing | |
| form 4 | Form 4 — LUCIANO JUAN R | View Filing | |
| form 4 | Form 4 — Sulzberger Gabrielle | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Yuffa Ilya | View Filing | |
| edgar index | 25-NSE — ELI LILLY & Co | View Filing | |
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| edgar index | 8-K — ELI LILLY & Co | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Fyrwald J Erik | View Filing | |
| form 4 | Form 4 — LUCIANO JUAN R | View Filing | |
| form 4 | Form 4 — Sulzberger Gabrielle | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| edgar index | SD — ELI LILLY & Co | View Filing | |
| edgar index | 424B2 — ELI LILLY & Co | View Filing | |
| edgar index | 8-K — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 144 — ELI LILLY & Co | View Filing | |
| edgar index | 424B2 — ELI LILLY & Co | View Filing | |
| edgar index | FWP — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — LILLY ENDOWMENT INC | View Filing | |
| form 4 | Form 4 — LILLY ENDOWMENT INC | View Filing | |
| edgar index | SCHEDULE 13G — ELI LILLY & Co | View Filing | |
| edgar index | 8-K — ELI LILLY & Co | View Filing | |
| edgar index | 10-Q — ELI LILLY & Co | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | PX14A6G — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | SCHEDULE 13G/A — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| form 4 | Form 4 — Fyrwald J Erik | View Filing | |
| form 4 | Form 4 — LUCIANO JUAN R | View Filing | |
| form 4 | Form 4 — Sulzberger Gabrielle | View Filing | |
| edgar index | DFAN14A — ELI LILLY & Co | View Filing | |
| edgar index | SCHEDULE 13G/A — ELI LILLY & Co | View Filing | |
| edgar index | DEF 14A — ELI LILLY & Co | View Filing | |
| edgar index | DEFA14A — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Fyrwald J Erik | View Filing | |
| form 4 | Form 4 — LUCIANO JUAN R | View Filing | |
| form 4 | Form 4 — Sulzberger Gabrielle | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| form 4 | Form 4 — Alvarez Ralph | View Filing | |
| edgar index | PRE 14A — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| form 4 | Form 4 — Dozier Eric | View Filing | |
| form 4 | Form 4 — Dozier Eric | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing | |
| edgar index | 4 — ELI LILLY & Co | View Filing |
- Trusted by 1M+ investors
- Global coverage
- Real-time market data
- Independent & unbiased
Join thousands making smarter investment decisions.
Get started for free